Chengdu Yimoufeng Biotechnology Co., Ltd.

Phase I: Primary Objective To assess the safety and tolerability of IMC001 to determine the recommended dose for Phase IIa (RP2D) Secondary Objectives To evaluate the preliminary antitumor activity of IMC001 To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of IMC001 Phase IIa: Primary Objective To assess the efficacy of IMC001 in subjects with solid tumors who have failed standard therapy Secondary Objectives To assess the safety and other efficacy endpoints of IMC001 To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of IMC001 Exploratory Objectives (Applicable to Phase I and IIa studies): To perform immunogenicity analysis, lentiviral genomic insertion site assays, and long-term follow-up including replicating lentivirus (RCL) assays. To assess cytokine changes before and after IMC001 administration and their correlation with efficacy and safety. To assess the correlation between changes in biomarkers before and after IMC001 administration and their correlation with efficacy and safety. To assess CAR-T cell phenotypic changes before and after IMC001 administration. To assess the correlation between changes in the tumor microenvironment in tumor tissue samples before and after IMC001 administration and their relationship to efficacy and safety. To explore the correlation between the above-mentioned and other relevant biomarkers and efficacy and safety.